FHL2 and ovarian serous cystadenocarcinoma: For prognosis, high FHL2 expression was associated with poor OS in patients with THCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney renal clear cell carcinoma (KIRC), HNSC, LUAD, ovarian serous cystadenocarcinoma (OV), and LUSC.